UBS Group
PRTK

UBS Group’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

UBS Group’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-175,300
Closed -$3.38M – 8079
2017
Q1 		$3.38M Buy
+175,300
New +$2.76M ﹤0.01% 2445

UBS Group's PRTK Position: Q3 2023 in Review

UBS Group sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2023, closing a stake of 8,284 shares — an estimated $18.3K sold.

UBS Group first reported a position in PRTK in Q4 2014 and held it in 31 quarters. The position peaked at $1.48M in Q2 2017. 0 funds tracked by Wall St. Rank hold PRTK as of Q3 2023.

  • UBS Group reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
  • UBS Group sold 8,284 Paratek Pharmaceuticals, Inc. shares in Q3 2023, an estimated $18.3K.
  • UBS Group first reported a position in Paratek Pharmaceuticals, Inc. in Q4 2014 and held it in 31 quarters.
  • UBS Group's Paratek Pharmaceuticals, Inc. position peaked at $1.48M in Q2 2017.
  • 0 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2023.

Based on UBS Group's 13F filing for Q3 2023, filed 9 Nov 2023.